New LaunchJun 15, 2026, 06:16 AM
Dr. Reddy's Launches Generic Bosutinib 400mg in US; Eligible for 180-Day Exclusivity
AI Summary
Dr. Reddy's Laboratories announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States on June 13, 2026. This launch expands the company's oncology portfolio and aims to improve patient access to affordable medicines. The product is a first-to-file and is eligible for 180-days of generic drug exclusivity for this strength in the U.S. Dr. Reddy's holds exclusive marketing rights, while MSN Laboratories developed and manufactured the product. The Bosulif® brand (400mg) had U.S. sales of approximately $253.8 million for the 12 months ended April 2026.
Key Highlights
- Dr. Reddy's launched Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States on June 13, 2026.
- The product is first-to-market and eligible for 180-days of generic drug exclusivity for this strength in the U.S.
- Dr. Reddy's holds exclusive marketing rights for the product in the United States.
- MSN Laboratories is responsible for the development and manufacturing of the product.
- The Bosulif® brand (400mg) had U.S. sales of approximately $253.8 million for the 12 months ended April 2026.
- The product is categorized as an Oncology (Tyrosine Kinase Inhibitor) medicine.
Price Impact
More from RDY